ClinicalTrials.Veeva

Menu

Monocyte Profiles in Critically Ill Patients With Pseudomonas Aeruginosa Sepsis (MIPSA)

U

University of Ulm

Status

Enrolling

Conditions

Pseudomonal Bacteraemia
Pseudomonas Infections
Critically Ill
Pseudomonas Urinary Tract Infection
Pseudomonas Septicemia
Sepsis, Severe
Pseudomonas Gastrointestinal Tract Infection
Pseudomonas; Pneumonia
Sepsis

Study type

Observational

Funder types

Other

Identifiers

NCT03044223
PSA_Sepsis_M_1_2

Details and patient eligibility

About

The present study focuses on patients with Pseudomonas aeruginosa (PSA) sepsis. The aim of the present study is to find out whether the M1 (pro-inflammatory) or M2 (anti-inflammatory) phenotype predominates in blood monocytes in critically ill patients with PSA-sepsis, and whether the severity of sepsis and outcome is associated with distinct monocyte phenotype and function.

Full description

During bacterial related sepsis, one of the key playing cells are macrophages, monocytes and T-lymphocytes (Hotchkiss et al., 2003). Macrophages and monocytes are supposed to be essential for the septic reaction to Gram-negative bacteria (Hotchkiss et al. 2003). Generally, there are two dominant types of macrophages: the pro-inflammatory M1 macrophage and the anti-inflammatory M2 macrophage (Mantovani et al., 2006). Similar to this macrophage characteristics, monocytes can also be categorized into pro-or anti-inflammatory. These macrophage/monocyte phenotypes can be differentiated in vitro from freshly isolated human blood monocytes using either GM-CSF giving raise to M1 macrophage/monocyte or M-CSF resulting in M2 macrophage/monocyte (Mantovani et al., 2006; Neu et al., 2013). Brunialti et al. (2012) have already demonstrated that the population of antiinflammatory M2 monocytes in septic patients is bigger than the pro-inflammatory M1 population. However, the authors did not further analyze the underlying mechanisms of M2 polarization nor did they identify the sepsis-causing pathogens.

In the present study, monocytes and macrophages of patients with Pseudomonas aeruginosa (PSA) sepsis are characterized by their surface marker expression profile via flow cytometry and cytokine pattern by ELISA in vivo and after ex-vivo LPS stimulation. In addition, an ex-vivo model system for PSA induced sepsis is validated. Blood of critically ill patients in the ICU infected with PSA is sampled to isolate peripheral blood mononuclear cells (PBMCs). Blood monocytes are analyzed for surface marker expression to determine the relative proportions of M1 and M2 monocytes in these patients and in healthy controls by flow cytometry

Enrollment

100 estimated patients

Sex

All

Ages

18 to 90 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • age > 18 years
  • critically ill patients with sepsis
  • microbiologically proven infection with Pseudomonas aeruginosa

Exclusion criteria

  • life expectancy < 24 hours
  • participation in other studies

Trial contacts and locations

1

Loading...

Central trial contact

Eberhard Barth, MD; Manfred Weiss, MD, MBA

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems